EcoDrugPlus

Farnesyltransferase, Caax Box, Beta

Ensembl ID : ENSTBEG00000012378
Gene Symbol: FNTB
1 Cross references
210 Possible Orthologues:

Fatty Acid Amide Hydrolase

Ensembl ID : ENSTBEG00000014394
Gene Symbol: FAAH
1 Cross references
131 Possible Orthologues:

Fibroblast Activation Protein Alpha

Ensembl ID : ENSTBEG00000005163
Gene Symbol: FAP
1 Cross references
127 Possible Orthologues:

Fibroblast Growth Factor 2

Ensembl ID : ENSTBEG00000001147
Gene Symbol: FGF2
1 Cross references
117 Possible Orthologues:

Fibroblast Growth Factor Receptor 2

Ensembl ID : ENSTBEG00000014396
Gene Symbol: FGFR2
1 Cross references
216 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 1

Ensembl ID : ENSTBEG00000009960
Gene Symbol: FLT1
1 Cross references
198 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 3

Ensembl ID : ENSTBEG00000015242
Gene Symbol: FLT3
1 Cross references
133 Possible Orthologues:

Fyn Related Src Family Tyrosine Kinase

Ensembl ID : ENSTBEG00000016328
Gene Symbol: FRK
1 Cross references
216 Possible Orthologues:

Galactosidase Alpha

Ensembl ID : ENSTBEG00000015849
Gene Symbol: GLA
1 Cross references
196 Possible Orthologues:

Galectin 1

Ensembl ID : ENSTBEG00000009873
Gene Symbol: LGALS1
1 Cross references
380 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha1

Ensembl ID : ENSTBEG00000003773
Gene Symbol: GABRA1
1 Cross references
202 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha2

Ensembl ID : ENSTBEG00000001195
Gene Symbol: GABRA2
1 Cross references
253 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).